These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32129680)

  • 1. The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations.
    Gintant G; Traebert M
    Expert Opin Drug Discov; 2020 Jun; 15(6):719-729. PubMed ID: 32129680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unlocking Personalized Biomedicine and Drug Discovery with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Fit for Purpose or Forever Elusive?
    de Korte T; Katili PA; Mohd Yusof NAN; van Meer BJ; Saleem U; Burton FL; Smith GL; Clements P; Mummery CL; Eschenhagen T; Hansen A; Denning C
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():529-551. PubMed ID: 31506008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research.
    Andrysiak K; Stępniewski J; Dulak J
    Pflugers Arch; 2021 Jul; 473(7):1061-1085. PubMed ID: 33629131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Narkar A; Willard JM; Blinova K
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
    Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
    Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
    Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
    Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
    AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes.
    Rosell-Hidalgo A; Bruhn C; Shardlow E; Barton R; Ryder S; Samatov T; Hackmann A; Aquino GR; Fernandes Dos Reis M; Galatenko V; Fritsch R; Dohrmann C; Walker PA
    Expert Opin Drug Metab Toxicol; 2024 Jul; 20(7):685-707. PubMed ID: 37995132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment.
    Yang X; Ribeiro AJS; Pang L; Strauss DG
    Toxicol Sci; 2022 Nov; 190(2):117-126. PubMed ID: 36099065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.